Form 8-K TG THERAPEUTICS, INC. For: Jul 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Goldman Sachs Upgrades TG Therapeutics (TGTX) to Neutral, 'Valuation reflects Briumvi outlook'
August 2, 2023 7:09 AM EDTGoldman Sachs analyst Corinne Jenkins upgraded TG Therapeutics (NASDAQ: TGTX) from Sell to Neutral with a price target of $12.00 (from $16.00).
The analyst comments "We upgrade TGTX to Neutral from Sell and lower our 12-month price target to $12 ($16 prior). TGTX shares closed -50% (vs. XBI -1.2%) following 2Q23 EPS, which included revenue of $16.0M, well... More
